One-Year Results of First-Line Treatment Strategies in Patients With Critical Limb Ischemia (CRITISCH Registry)

Author:

Stavroulakis Konstantinos12ORCID,Borowski Matthias3,Torsello Giovanni12,Bisdas Theodosios12,Adili Farzin,Balzer Kai,Billing Arend,Böckler Dittmar,Brixner Daniel,Debus E. Sebastian,Eckstein Hans-Henning,Florek Hans-Joachim,Gkremoutis Asimakis,Grundmann Reinhardt,Hupp Thomas,Keck Tobias,Gerß Joachim,Wojciech Klonek,Lang Werner,May Björn,Meyer Alexander,Mühling Bernhard,Oberhuber Alexander,Reinecke Holger,Reinhold Christian,Ritter Ralf-Gerhard,Schelzig Hubert,Schlensack Christian,Schmitz-Rixen Thomas,Schulte Karl-Ludwig,Spohn Matthias,Steinbauer Markus,Storck Martin,Trede Matthias,Uhl Christian,Weis-Müller Barbara,Wenk Heiner,Zeller Thomas,Zhorzel Sven,Zimmermann Alexander

Affiliation:

1. Department of Vascular Surgery, St Franziskus Hospital GmbH, Münster, Germany

2. Department of Vascular Surgery, University Clinic of Münster, Germany

3. Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Germany

Abstract

Purpose: To examine the outcomes of all first-line strategies for the treatment of critical limb ischemia (CLI), identify factors that influenced the treatment choice, and determine the risk of amputation or death after each treatment. Methods: CRITISCH ( ClinicalTrials.gov identifier NCT01877252) is a multicenter, national, prospective registry evaluating all available treatment strategies applied in 1200 consecutive CLI patients in 27 vascular centers in Germany. The recruitment started in January 2013 and was completed in September 2014. Treatment options were endovascular revascularization (642, 53.5%), bypass surgery (284, 23.7%), femoral artery patchplasty (126, 10.5%) with or without concomitant peripheral intervention, conservative treatment (118, 9.8%), and primary major amputation (30, 2.5%). The primary endpoint of this study was amputation-free survival (AFS). The Society of Vascular Surgery’s suggested objective performance goal (OPG) for AFS (71%) was used as the effectiveness criterion. Multivariable regression methods were employed to identify variables that influenced the treatment selection and AFS after each treatment; results are presented as the hazard ratio (HR) and 95% confidence interval (CI). Results: The 12-month AFS estimates following endovascular therapy, bypass grafting, femoral patchplasty, and conservative treatment were 75%, 72%, 73%, and 72%, respectively. Factors influencing treatment choice were age, chronic kidney disease (CKD), diabetes, smoking, prior vascular procedures in the index leg, TransAtlantic Inter-Society Consensus II C/D lesions, and absence of runoff vessels. Cox regression analysis identified CKD (HR 2.07, 95% CI 1.26 to 3.41, p=0.004), the use of a prosthetic bypass conduit (HR 1.97, 95% CI 1.23 to 3.14, p=0.004), and previous vascular intervention in the index limb (HR 1.52, 95% CI 0.94 to 2.43, p=0.085) as independent risk factors for diminished AFS after bypass surgery. CKD (HR 1.47, 95% CI 1.09 to 1.99, p=0.012) and Rutherford category 6 (HR 1.81, 95% CI 1.30 to 2.52, p<0.001) compromised the performance of endovascular revascularization. Conclusion: CRITISCH registry data revealed that all first-line treatment strategies selected and indicated by the treating physicians met the suggested OPGs. CKD was an important determinant of patient prognosis after treatment regardless of the revascularization method.

Funder

The German Society of Vascular Surgery and Medicine (Deutsche Gesellschaft für Gefäßchirurgie and Gefäßmedizin) sponsored this study

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3